Arca
Skip to content

Respiratory syncytial virus

Drug research and approvals for respiratory syncytial virus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 55 studies of respiratory syncytial virus are recruiting on ClinicalTrials.gov, Health Canada has authorized 50 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 55
  • Trials authorized in Canada: 50
  • FDA orphan approvals: 1
  • EU medicines: 6

Recruiting Now

Newest start dates first, of 55 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 50; search them all in Canada trials
Sep 18, 2024A phase 3, global, randomized, modified double-blind, placebo-controlled, study to evaluate the efficacy, immunogenicity, and safety of ivx-a12, a respiratory…IVX-A12ICOSAVAX INC. (ICOSAVAX) (A MEMBER OF THE ASTRAZENECA GROUP OF COMPANIES)Pending
Jun 3, 2024A phase 3 study to evaluate the efficacy, immunogenicity and safety of respiratory syncytial (rsv) perfusion f subunit vaccine in adultsABRYSVOPfizerOngoing
Mar 22, 2024A phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the rsvpref3 oa investigational vaccine in…RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE BIO RSV OA=ADJ (GSK3844766A)GSKOngoing
Dec 5, 2023A phase 2, randomized, observer-blind, placebo-controlled, dose-escalation study to evaluate the reactogenicity, safety, and immunogenicity of mrna- 1345, an…MRNA-1345MODERNATX, INC.Closed
Nov 2, 2023An interventional phase 2/3, adaptive, multi-center, randomized, double-blind study to investigate efficacy and safety of oral sisunatovir compared with…SISUNATOVIR (PF-07923568)PfizerOngoing
Aug 10, 2023An interventional, phase 1b, randomized, double-blind, sponsor-open, placebo-controlled, multi-center, dose-finding study to evaluate safety, tolerability and…SISUNATOVIR (PF-07923568)PfizerClosed
Jun 30, 2023A phase 1, open-label, age-descending, dose-finding study and a phase 2/3, placebo-controlled, randomized, double-blind study to evaluate the safety,…PF-06928316 (RESPIRATORY SYNCYTIAL VIRUS [RSVPREF] VACCINE)PfizerPending
Jun 23, 2023A phase 3 study to evaluate the immunogenicity and safety of mrna-1345, an mrna vaccine targeting respiratory syncytial virus, in high-risk adultsMRNA-1345MODERNATX, INC.Ongoing
Jun 8, 2023A phase 1, randomized, observer-blind, placebo-controlled, age de-escalation study of the safety, tolerability, and immunogenicity of mrna-1345 and mrna-1365…MRNA-1345 / MRNA-1365MODERNATX, INC.Pending
Jun 1, 2023A phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of rsvpref3 oa investigational…RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION PROTEIN F3 OLDER ADULT (RSVPREF3…GSKOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Jan 18, 1996RespigamFor the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary…MedImmune & Massachussetts Public Health Biologics Labs.Approved
Sep 27, 1990Respiratory Syncytial Virus Immune Globulin (human)Treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.MedImmune, Inc.Designated
Jan 3, 1989Aerosolized pooled immune globulinTreatment of respiratory syncytial virus lower respiratory tract disease.Pediatric Pharmaceuticals, Inc.Designated

Medicines Authorised in the EU

Newest first
Apr 15, 2026EnflonsiaclesrovimabMerck Sharp Dohme LimitedEMA ↗
Aug 22, 2024mResviarespiratory syncytial virus mRNA vaccineModerna Biotech Spain, S.L.EMA ↗
Aug 23, 2023Abrysvorespiratory syncytial virus vaccine (bivalent, recombinant)Pfizer Europe MA EEIGEMA ↗
Jun 6, 2023ArexvyRespiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)GlaxoSmithKline Biologicals S.A.EMA ↗
Oct 31, 2022BeyfortusnirsevimabSanofi Winthrop IndustrieEMA ↗
Aug 13, 1999SynagispalivizumabAstraZeneca ABEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.